Original article:

ANTIDIABETIC ACTIVITY OF THE CHEMICAL CONSTITUENTS OF COMBRETUM DOLICHOPETALUM ROOT IN MICE

Philip F. Uzor*, Patience O. Osadebe

Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, 410001, Enugu State, Nigeria

* Corresponding author: E-mail: philip.uzor@unn.edu.ng; Tel: +234-8037008294

http://dx.doi.org/10.17179/excli2016-252

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

ABSTRACT

The root of *Combretum dolichopetalum* (Combretaceae) is used in ethnomedicine for the management of diabetes mellitus. Though some compounds have been isolated from it, the antidiabetic principles have not been identified. The present study was designed to evaluate the chemical constituents from the root of *C. dolichopetalum* with a view to identifying the antidiabetic principles. The constituents include the alkaloids, echinulin (1) and arestrictin B (2), the terpenoids, arjunolic acid (3) and 4'-dihydrophaseic acid (4) as well as the phenolic acids, ellagic acid (5) and 3, 4, 3'-tri-O-methylellagic acid (6). Twenty eight mice (in seven groups, n = 4) were made diabetic using alloxan monohydrate (*i.p.*, 120 mg/kg) and treated orally with either the vehicle (control group), any of the constituents or glibenclamide (standard drug). The fasting blood glucose of the diabetic animals was monitored for nine hours. Results showed that all the chemical constituents (1-6) exhibited significant (*p* < 0.05) antidiabetic activity comparable to glibenclamide. The alkaloids exhibited the most profound antidiabetic activity. The present study has thus identified the antidiabetic principles of *C. dolichopetalum* root as echinulin, arestrictin B, arjunolic acid, 4'-dihydrophaseic acid, ellagic acid and 3, 4, 3'-tri-O-methylellagic acid. The study has further validated the ethnomedicinal use of the root of *C. dolichopetalum* in diabetes.

Keywords: Antidiabetic constituents, arjunolic acid, *Combretum dolichopetalum*, combretaceae, echinuline, ellagic acid

INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder which is characterized by hyperglycemia and long term complications such as retinopathy, nephropathy, neuropathy, and angiopathy. Diabetes remains one of the leading causes of death worldwide. The 2015 estimate by the International Diabetes Federation (IDF) shows that 1 in 11 adults have diabetes (415 million) and the figure is projected to rise to 1 adult in 10 (642 million) in 2040. The estimate also shows that diabetes caused 5.0 million deaths implying that every six seconds a person dies from diabetes. This metabolic disorder caused at least USD 673 billion, representing 12% of global health expenditure (IDF, 2015). The increasing worldwide incidence of diabetes constitutes a significant impact on the health, quality of life, and life expectancy of patients, as well as on the global public health care system.

In conventional practice, management of type 1 diabetes is by exogenous insulin while type 2 is by oral agents including the sulfonylureas, biguanides, α-glucosidase inhibitors, glitazones, gliptins, and the SGLT 2 inhibitors, which are used as monotherapy or in combination to achieve better glycemic
regulation since they have different modes of action. Despite the existing pharmacotherapy, it is still difficult to attain adequate glycemic control amongst many diabetic patients due to the progressive decline in β-cell function (Wallace and Matthews, 2000). Moreover, many of these oral antidiabetic agents have a number of serious adverse effects (Pepato et al., 2005). The low efficacy and the adverse effects of some of the conventional antidiabetic agents together with the increasing global incidence of diabetes necessitate the urgent search for more potent and safer alternatives from natural sources such as medicinal plants.

As part of our on-going search for antidiabetic agents from natural sources (Osadebe et al., 2014; Uzor et al., 2014), we have furthered our investigation on the root of Combretum dolichopetalum (Combretaceae) Engl. and Diels. The plant is a scandent shrub or forest liana. The root extract is used in traditional medicine for dysentery, indigestion and in the management of diabetes (Uzor et al., 2014). The antisecretory (Asuzu and Onu, 1990), anti-hepatotoxic (Udem et al., 1997) and trypanocidal (Udem et al., 1996) activities of this plant have been reported. We have recently investigated the antidiabetic activity of the root extract and fractions of this plant on diabetic animals and established that the antidiabetic fractions contain steroids, terpenoids, alkaloids and flavonoids (Uzor et al., 2014). Additionally, our more recent chemical investigation led to the isolation of six known metabolites (Figure 1) from the root of the plant, including the alkaloids echinulin (1) and arestrictin B (2), terpenoids, arjunolic acid (3) and 4'-dihydrophaseic acid (4), as well as phenolic acids ellagic acid (5) and 3, 4, 3'-tri-O-methyl ellagic acid (6) (Uzor et al., 2015). These compounds were investigated for their cytotoxic potentials using the L5178Y mouse lymphoma cell lines but their antidiabetic potentials have not been assessed. Thus the antidiabetic constituents of the root of this plant have not been identified. The current study was therefore designed to evaluate the antidiabetic activity of the isolated constituents from the root of this plant. To the best of our knowledge, this is the first report of antidiabetic compounds from C. dolichopetalum root.

![Figure 1: Isolated compounds from C. dolichopetalum root](image-url)
EXPERIMENTAL

Chemicals
Alloxan monohydrate was purchased from Sigma-Aldrich while glibenclamide was purchased from NGC. All other chemicals were of analytical grade.

Plant material
Roots of *Combretum dolichopetalum* were collected in Nsukka, Nigeria, in April 2014 and identified by Mr. A. Ozioko, a taxonomist with the International Center for Ethnomedicine and Drug Development (InterCEDD), Nsukka. A voucher specimen (InterCEDD/853) is deposited at the Herbarium of the Department of Pharmaceutical and Medicinal Chemistry, University of Nigeria, Nsukka.

Extraction and isolation
The procedures for the isolation of the constituents of *C. dolichopetalum* root to obtain 1-6 have been recently described (Uzor et al., 2015). Compounds 1 and 2 (or 1/2), two isomeric indole-containing diketopiperazine alkaloids, were obtained as a mixture (56:54). They were thus evaluated as one sample.

Animals
Swiss albino mice (18.0–24.2 g) of either sex were used for the studies. The animals were kept in standard polypropylene cages at room temperature and 60-65 % relative humidity during the experimental work with 12 h day: 12 h night cycle. They were fed with normal laboratory diet and allowed to drink water *ad libitum*. The experimental protocols followed the guidelines of the Ethics Committee of the University of Nigeria and the European Community guidelines (EEC Directive of 1986; 86/609/EEC) (EEC, 1986).

Antidiabetic study
Twenty eight (28) albino mice were fasted for 12 h prior to induction of hyperglycemia. Diabetes was induced using freshly prepared solution of alloxan monohydrate (*i.p.* at 120 mg/kg body weight) as previously reported (Uzor et al., 2014). After the induction, the diabetic animals were randomly divided into seven groups (n = 4) and treated orally according to the following protocols:
- Group A: alloxan + 2 mL/kg of vehicle
- Group B: alloxan +20 mg/kg of 1/2
- Group C: alloxan + 20 mg/kg of 3
- Group D: alloxan + 10 mg/kg of 4
- Group E: alloxan + 20 mg/kg of 5
- Group F: alloxan + 20 mg/kg of 6
- Group G: alloxan + 0.2 mg/kg of glibenclamide

Blood sample was withdrawn from the tail vein and fasting blood glucose (FBG) was measured with a glucometer (Accu-chek®, Roche) at 0, 1, 3, 6 and 9 h. Mice model was used since the compounds were limited in quantity.

Statistical analysis
The data obtained were analyzed using a statistical software (SPSS version 21) and results expressed as mean ± SEM. The means were subjected to one way analysis of variance (ANOVA) for determining the significant difference. The significance between the various groups and the control was analyzed further by *post hoc* Dunnet’s test (2-sided). Group mean was considered to be significantly different from that of the control group at $p < 0.05$.

RESULTS
The results of the antidiabetic activities of the isolated chemical constituents are shown in Table 1. All the constituents (1-6) exhibited significant ($p < 0.05$) reduction of the FBG of the diabetic mice after 3 h but the effect of the alkaloids, (1/2), was most pronounced and sustained. The antidiabetic effect of the alkaloids was maximal at 3 h after administration (53.40 % reduction of FBG). Among the constituents, 1/2 was followed in antidiabetic potency by 5 (23.7 % maximal reduction in 9 h), 6 (22.7 % reduction in 3 h), 4 (17.91 % maximal reduction of FBG in 6 h), and then by 3 (17.27 % reduction in
Table 1: Effect of the chemical constituents from *C. dolichopetalum* root on the FBG of alloxan-induced diabetic mice

| Group | Treatment          | Basal  | FBG (mg/dL)   | Time (h) |
|-------|--------------------|--------|---------------|----------|
|       |                    |        | 0     | 1       | 3       | 6       | 9       |
| A     | Control (vehicle)  | 77.00  | 221.25 ± 17.93 | 246.25 ± 20.78 | 350.50 ± 15.71 | 256.25 ± 42.53 | 278.50 ± 27.39 |
| B     | 1/2 (20 mg/kg)    | 63.50* | 249.00 ± 39.01 | 218.00 ± 25.54 | 116.00*** | 158.00 ± 46.70 | 238.75 ± 43.11 |
|       | (12.45 %)         |        | (12.45 %)     | (53.40 %) | (36.55 %) | (4.12 %)         |
| C     | 3 (20 mg/kg)      | 66.25  | 250.50 ± 35.44 | 256.25 ± 21.68 | 207.25*** | 224.75 ± 27.79 | 238.75 ± 33.46 |
|       | (-2.20 %)         |        | (-2.20 %)     | (17.27 %) | (10.40 %) | (-11.18 %)       |
| D     | 4 (10 mg/kg)      | 63.50* | 353.25** ± 17.14 | 339.00** ± 12.50 | 302.75* | 290.00 ± 4.08 | 296.00 ± 4.85 |
|       | (-4.03 %)         |        | (4.03 %)      | (14.30 %) | (17.91 %) | (16.21 %)        |
| E     | 5 (20 mg/kg)      | 62.00* | 267.50 ± 18.39 | 278.75 ± 12.16 | 220.75*** | 224.00 ± 17.33 | 204.50 ± 27.29 |
|       | (-4.20 %)         |        | (-4.20 %)     | (17.48 %) | (16.26 %) | (23.55 %)        |
| F     | 6 (20 mg/kg)      | 66.50  | 210.25 ± 18.87 | 226.25 ± 11.81 | 162.50*** | 259.75 ± 35.51 | 218.50 ± 28.71 |
|       | (-7.61 %)         |        | (7.61 %)      | (22.71 %) | (-23.54 %) | (-3.90 %)       |
| G     | Glibenclamide (0.2 mg/kg) | 56.25*** | 253.00 ± 10.07 | 156.25** ± 10.14 | 146.50*** | 144.50** ± 6.65 | 129.75*** ± 1.31 |
|       | (38.24 %)         |        | (38.24 %)     | (42.10 %) | (42.89 %) | (48.72 %)       |

Results are expressed as mean ± SEM (n = 4). *p < 0.05, **p < 0.01, ***p < 0.001, as compared with Control group (one way ANOVA followed by Dunnet’s t-test). Values in parenthesis denote percentage reduction of blood glucose from 0 h.

3 h). Even at 10 mg/kg, 4 exhibited significant antidiabetic activity by lowering the FBG (17.91 %) of the diabetic mice. Overall, the effect of the compounds was comparable to that of glibenclamide (reduction of 48.72 % in 9 h).

**DISCUSSION**

The present study has shown that the compounds from the root of *C. dolichopetalum* possess antidiabetic activity. The present observation validates the traditional use of the plant in diabetes. Other plant species from Combretaceae have been known to contain diverse chemical constituents such as ellagic acid, gallic acid, ellagitannins and gallotannins; they have been also known for a long time to show pharmacological effects like antioxidant, antibacterial and antidiabetic activities (Sabu and Kuttan, 2002). Previous report shows that echinuline (1) exhibits moderate protein tyrosine phosphatase 1B (PTP1B) inhibitory activity (Sohn et al., 2013) which suggests the possible antidiabetic activity of 1. The biological activity of arestrictin B (2) was not evaluated in a study where it was first isolated in a pure form from xerophilic fungi (Itabashi et al., 2006). Thus it is possible that one or both of the two isomeric alkaloids possess antidiabetic activity or they could be acting synergistically. Further studies on the separation of the alkaloids and evaluation of their individual antidiabetic activities are envisaged. These two compounds have been isolated singly espe-
cially from fungal sources but they were reported, for the first time, as having occurred together in *C. dolichopetalum* root (Uzor et al., 2015).

Similar to the alkaloids above, our findings showed that arjunolic acid (3) was one of the antidiabetic constituents of *C. dolichopetalum*. The triterpenoid, 3, is also possibly acting synergistically with other bioactive constituents. Previous reports support our present observation. Compound 3 was isolated from *Lagerstroemia speciosa* leaves and tested for its alpha glucosidase activity using yeast alpha glucosidase enzyme. It was shown that 3 inhibited the enzyme with IC$_{50}$ of 18.63 ± 0.32 µg/mL while the standard drugs, acarbose and voglibose, showed no inhibition (Hou et al., 2009). Other studies have also supported the beneficial role of 3 in diabetes (Ghosh and Sil, 2013; Manna et al., 2009a, b; Manna and Sil, 2012).

The results of the present study have shown that dihydrophaseic acid (4), a derivative of S(+)-abscisic acid (ABA) (Hirai et al., 2003) exhibits significant (p < 0.05) antidiabetic property. ABA, a plant hormone, has been shown to exhibit antidiabetic effect through peroxisome proliferator-activated receptor gamma (PPAR $\gamma$) activation (Guri et al., 2010). It is therefore possible that 4 exhibits its antidiabetic activity through PPAR $\gamma$ activation similar to its precursor, ABA. The present study is probably the first report of the antidiabetic activity of this ABA metabolite. However, one study shows that 4 exhibited some biological activities such as cytotoxicity, lipid peroxidation inhibition effect, mild hydroxyl radical scavenging activity, and DNA protective effect (Lin et al., 2014).

We have also observed that ellagic acid (5) was one of the bioactive antidiabetic principles of *C. dolichopetalum* root. Previous study has demonstrated the antidiabetic activity of 5 in vivo (Malini et al., 2011). Moreover, 5 has been widely reported as an inhibitor of aldose reductase enzyme and inhibitor of the formation of advanced glycation end products (Kim et al., 2008). Aldose reductase inhibitors are an attractive pharmacological target for the treatment of diabetic complications. Compound 6, which is a methylated derivative of 5 also showed *in vivo* antidiabetic activity in the present study. Earlier studies showed the $\alpha$-glucosidase inhibitory effect of the methylated derivatives of 5 (Tabopda et al., 2008). Furthermore, methylated derivatives of 5 are known to play some roles in antidiabetic activities of plants. While 6 showed glucose transport stimulatory activity, 5 did not show such activity (Bai et al., 2008). This suggests that methylation of the OH group of 5 is necessary for antidiabetic activity.

**CONCLUSION**

The present study has shown that all the isolated constituents of *C. dolichopetalum* root including the alkaloids (echinulin and arestrictin B), arjunolic acid, 4’-dihydrophaseic acid, ellagic acid and as 3, 4, 3’-tri-O-methylellagic acid were identified as the major antidiabetic active principles of the plant. It is possible that these metabolites exert synergistic effect in their antidiabetic activities. The study has further validated the ethnomedicinal use of the root of *C. dolichopetalum* in the management of diabetes.

**Acknowledgement**

The authors are grateful to the Institute of Pharmaceutical Biology and Biotechnology, Universität Dusseldorf for HPLC and NMR measurement of the isolated compounds. They are also grateful to Mr. O. Ezeugwu for assistance in sourcing the plant materials and Mr. A. Ozioko for the identification of the plant.

**Conflict of interest**

No conflict of interest is associated with this work.
REFERENCES

Asuzu IU, Onu OU. Anti-ulcer activity of the ethanol-ic extract of *Combretum dolichopetalum* roots. Int J Crude Drug Res. 1990;28:27–32.

Bai N, He K, Roller M, Zheng B, Chen X, Shao Z, et al. Active compounds from *Lagerstroemia speciosa*, insulin-like glucose uptake-stimulatory/inhibitory and adipocyte differentiation-inhibitory activities in 3T3-L1 Cells. J Agric Food Chem. 2008;56:11668–74.

EEC. Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Off J Eur Commun. 1986;L358:1-29.

Ghosh J, Sil PC. Arjunolic acid:a new multifunctional therapeutic promise of alternative medicine. Biochimie. 2013;95:1098-109.

Guri AJ, Hontecillas R, Bassaganya-Riera J. Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue:possible action of the cAMP/PKA/PPA γ axis. Clin Nutr. 2010;29:646-53.

Hirai N, Kondo S, Ohigashi H. Deuterium-labelled phaseic acid and dihydrophaseic acids for internal standards. Biosci Biotech Biochem. 2003;67:2408-15.

Hou W, Li Y, Zhang Q, Wei X, Peng A, Chen L, et al. Triterpene acids isolated from *Lagerstroemia speciosa* leaves as α-glucosidase inhibitors. Phytother Res. 2009;23:614–8.

International Diabetes Federation (IDF). IDF diabetes atlas. 7th ed. Brussels: IDF, 2015. [http://www.diabetesatlas.org/key-messages.html](http://www.diabetesatlas.org/key-messages.html). Accessed 08 April 2016.

Itabashi T, Matsuis N, Hosoe T, Toyazaki N, Udagwa S, Imai T, et al. Two new dioxopiperazine derivatives, arestrictins A and B, isolated from *Aspergillus restrictus* and *Aspergillus penicilloides*. Chem Pharm Bull. 2006;54:1639-41.

Kim JM, Jang DS, Lee YM, Yoo JL, Kim YS, Kim JH, et al. Aldose-reductase-and protein-glycation-inhibitory principles from the whole plant of *Du Chesnea chrysanth*. Chem Biodivers. 2008;5:352-6.

Lin S, He J, Jiang Y, Wu F, Wang H, Wu H, et al. Production of nigragillin and dihydrophaseic acid by biotransformation of litchi pericarp with *Aspergillus awamori* and their antioxidant activities. J Funct Food. 2014;7:278–86.

Malini P, Kanchana G, Rajadurai M. Antiabetic efficacy of ellagic acid in streptozotocin induced diabetes mellitus in albino wistar rats. Asian J Pharm Clin Res. 2011;4:124-8.

Manna P, Sil PC. Arjunolic acid:beneficial role in type 1 diabetes and its associated organ pathophysiology. Free Radic Res. 2012;46:815-30.

Manna P, Sinha M, Sil PC. Prophylactic role of arjunolic acid in response to streptozotocin mediated diabetic renal injury:activation of polyol pathway and oxidative stress responsive signaling cascades. Chem Biol Interact. 2009a;181:297-308.

Manna P, Sinha M, Sil PC. Protective role of arjunolic acid in response to streptozotocin-induced type-I diabetes via the mitochondrial dependent and independent pathways. Toxicology. 2009b;257:53-63.

Osadebe PO, Uzor PF, Omeje EO, Agbo MO, Obonga WO. Hypoglycemic activity of the extract and fractions of *Anthocleista vogelli* (Planch) stem bark. Trop J Pharm Res. 2014;13:1437-43.

Pepato MT, Mori DM, Baviera AM, Harami JB, Vendramini RC, Brunetti IL. Fruit of the Jambolan tree and experimental diabetes. J Ethnopharmacol. 2005;96:43-8.

Sabu MC, Kuttan CR. Anti-diabetic activity of medicinal plants and its relationship with their antioxidant property. J Ethnopharmacol. 2002;81:155–60.

Sohn JH, Lee Y-R, Lee D-S, Kim Y-C, Oh H. PTP1B inhibitory secondary metabolites from marine-derived fungal strains *Penicillium* spp. and *Eurotium* sp. J Microbiol Biotechnol. 2013;23:1206-11.

Tabopda TK, Ngoupayo J, Liu J, Ali MS, Khan SN, Ngadjui BT, et al. α-glucosidase inhibitors ellagic acid derivatives with immunoinhibitory properties from *Terminalia superba*. Chem Pharm Bull. 2008;56:847-50.

Udem SC, Madubunyi I, Asuzu IU, Anika SM. The trypanocidal action of the root extract of *Combretum dolichopetalum*. Fitoterapia. 1996;67:31–7.

Udem SC, Madubunyi I, Okoye JOA, Anika SM. Anti-hepatotoxic effects of the Ethanolic extracts of *Combretum dolichopetalum* root bark and *Morinda lucida* leaf. Fitoterapia. 1997;68:21–4.

Uzor PF, Osadebe PO, Omeje EO, Agbo MO. Bioassay guided isolation and evaluation of the anti diabetic principles of *Combretum dolichopetalum* root. Br J Pharm Res. 2014;4:2155-71.
Uzor PF, Ebrahim W, Osadebe PO, Nwodo JN, Okoye FB, Müller WEG, et al. Metabolites from *Combretum dolichopetalum* and its associated endophytic fungus *Nigrospora oryzae* – Evidence for a metabolic partnership. Fitoterapia. 2015;105:147–50.

Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. Quart J Med. 2000;93:369–74.